Actinium s Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia

NEW YORK - Actinium Pharmaceuticals, Inc. , a leader in the development of targeted radiotherapies, today highlighted four presentations at the 65th Annual American Society of Hematology Annual...

Related Keywords

United States ,American ,Sandesh Seth ,Astellas Pharma ,Actimaba National Cancer Institute ,American Society Of Hematology Annual Meeting Exposition ,Oncology Lg Chem Life Sciences ,Actinium Pharmaceuticals Inc ,Exchange Commission ,Hematology Annual Meeting ,Multiple High Risk ,Complete Remission ,Karnofsky Performance Status ,National Cancer Institute ,Life Sciences ,News Publishing ,Markets ,